A detailed history of Black Rock Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Black Rock Inc. holds 7,898,585 shares of SMMT stock, worth $150 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,898,585
Previous 9,823,341 19.59%
Holding current value
$150 Million
Previous $40.7 Million 51.49%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.39 - $10.92 $4.6 Million - $21 Million
-1,924,756 Reduced 19.59%
7,898,585 $61.6 Million
Q1 2024

May 10, 2024

BUY
$2.55 - $5.07 $163,092 - $324,267
63,958 Added 0.66%
9,823,341 $40.7 Million
Q4 2023

Feb 13, 2024

BUY
$1.67 - $2.83 $1.31 Million - $2.21 Million
782,464 Added 8.72%
9,759,383 $25.5 Million
Q3 2023

Nov 13, 2023

BUY
$1.54 - $2.42 $329,680 - $518,068
214,078 Added 2.44%
8,976,919 $16.8 Million
Q2 2023

Aug 11, 2023

BUY
$1.32 - $2.81 $9.13 Million - $19.4 Million
6,917,788 Added 374.94%
8,762,841 $22 Million
Q1 2023

May 12, 2023

BUY
$1.38 - $5.41 $1.81 Million - $7.09 Million
1,310,393 Added 245.09%
1,845,053 $3.23 Million
Q4 2022

Feb 13, 2023

BUY
$0.68 - $5.31 $77,230 - $603,077
113,574 Added 26.97%
534,660 $2.27 Million
Q3 2022

Nov 14, 2022

BUY
$0.89 - $1.63 $105,801 - $193,771
118,878 Added 39.34%
421,086 $500,000
Q2 2022

Aug 12, 2022

SELL
$0.92 - $2.38 $977,946 - $2.53 Million
-1,062,985 Reduced 77.86%
302,208 $302,000
Q1 2022

May 12, 2022

SELL
$2.0 - $3.45 $71,094 - $122,637
-35,547 Reduced 2.54%
1,365,193 $3.34 Million
Q4 2021

Feb 10, 2022

BUY
$2.45 - $5.64 $490,367 - $1.13 Million
200,150 Added 16.67%
1,400,740 $3.77 Million
Q3 2021

Nov 09, 2021

BUY
$4.83 - $8.27 $509,289 - $872,013
105,443 Added 9.63%
1,200,590 $6.02 Million
Q2 2021

Aug 11, 2021

BUY
$5.15 - $8.46 $5.64 Million - $9.26 Million
1,095,147 New
1,095,147 $8.17 Million

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.81B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.